BEVERLY, Mass. and TORONTO, April 30, 2018 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced the introduction of its next generation of laser system software for its clinical laser systems.

Hamilton Thorne’s HT Laser 6 software, coupled with a new 5-megapixel digital camera offers users:

• All new user interface to improve ease of use
• Higher resolution video output for enhanced imaging, including full-screen view
• Integrated patient database for data capture and linking to existing laboratory information systems
• New reporting tools allowing the user to design unlimited reports
• Multilingual support for English, Chinese, French, German, Japanese, Russian, and Spanish end users

David Wolf, President and Chief Executive Officer stated, “Listening to the needs of IVF professionals is a key element to innovation and success at Hamilton Thorne. The introduction of our HT Laser 6 software reflects our continued commitment to providing our customers with the most up-to-date technology to better serve their patients. Updating our software and imaging capabilities provides us with a solid foundation to continue innovating for the future.”

The HT Laser 6 software equipped with the new 5-megapixel digital camera will be available in May 2018 for all new purchases; existing clinical laser users will be offered a cost-effective upgrade path. Hamilton Thorne expects to update the software and camera options for its research lasers and its CIVA imaging system over the balance of 2018.

About Hamilton Thorne Ltd. (https://www.hamiltonthorne.com)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict including the risk that the Company may not be able to obtain the necessary regulatory approvals, as applicable. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com